{"status":"success","data":{"title":"IV Fluid Formulations for ICU Patients","slug":"iv-fluids-for-icu-patients","tags":null,"collection":["Critical Care"],"content":"<h1 id=\"intravenous-fluid-formulations-and-chloride-restrictive-iv-fluids-for-icu-patients\">Intravenous Fluid Formulations and Chloride-Restrictive IV Fluids for ICU Patients</h1>\n<table>\n<thead>\n<tr>\n<th>Content per 1 L</th>\n<th>Lactated Ringer&#39;s</th>\n<th>Normal Saline (0.9%)</th>\n<th>Plasma-Lyte 148</th>\n<th>D5W</th>\n<th>D5 1/2NS</th>\n<th>5% albumin</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Na (mEq)</td>\n<td>130</td>\n<td>154</td>\n<td>140</td>\n<td></td>\n<td>77</td>\n<td>130-160</td>\n</tr>\n<tr>\n<td>K (mEq)</td>\n<td>4</td>\n<td></td>\n<td>5</td>\n<td></td>\n<td></td>\n<td>&lt; 1</td>\n</tr>\n<tr>\n<td>Cl (mEq)</td>\n<td>109</td>\n<td>154</td>\n<td>98</td>\n<td></td>\n<td>77</td>\n<td>130-160</td>\n</tr>\n<tr>\n<td>Ca (mEq)</td>\n<td>3</td>\n<td></td>\n<td></td>\n<td></td>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td>Mg (mEq)</td>\n<td></td>\n<td></td>\n<td>3</td>\n<td></td>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td>Lactate (mEq)</td>\n<td>28</td>\n<td></td>\n<td></td>\n<td></td>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td>Acetate (mEq</td>\n<td></td>\n<td></td>\n<td>27</td>\n<td></td>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td>Gluconate (mEq)</td>\n<td></td>\n<td></td>\n<td>23</td>\n<td></td>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td>Glucose (mg/dL)</td>\n<td></td>\n<td></td>\n<td></td>\n<td>4545</td>\n<td>4545</td>\n<td></td>\n</tr>\n<tr>\n<td>Osmolarity (mOsm/L)</td>\n<td>273</td>\n<td>308</td>\n<td>294</td>\n<td>252</td>\n<td>406</td>\n<td>309</td>\n</tr>\n<tr>\n<td>pH</td>\n<td>6.5</td>\n<td>5.0</td>\n<td>5.0</td>\n<td>4.0</td>\n<td>4.5</td>\n<td>6.4-7.4</td>\n</tr>\n<tr>\n<td>Other</td>\n<td></td>\n<td></td>\n<td></td>\n<td></td>\n<td></td>\n<td>50 g/L  albumin</td>\n</tr>\n</tbody>\n</table>\n<p><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=23073953\">Yunos et al JAMA 2012 study:</a></p>\n<ul>\n<li>Prospective open, label sequential study of 760 ICU patients (control) and 773 ICU patients (study group) at single hospital in Melbourne, Australia</li>\n<li>Control period: Standard IVF per physician preference</li>\n<li>Study period: Chloride-rich IVF (0.9% saline, 4% succinylated gelatin solution, 4% albumin) became restricted and required specialist approval. Standard fluids allowed were chloride-restrictive fluids (Hartmann solution – similar to lactated ringer’s, Plasma-Lyte 148, chloride-poor 20% albumin)</li>\n</ul>\n<table>\n<thead>\n<tr>\n<th></th>\n<th>Control period (Chloride-liberal)</th>\n<th>Study period (Chloride-restricted)</th>\n<th>P value</th>\n<th>Odds ratio for Cl-restrictive  fluid use</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Mean serum Cr increased in umol/L</td>\n<td>22.6 (0.26 mg/dL)</td>\n<td>14.8 (0.17 mg/dL)</td>\n<td>0.3</td>\n<td></td>\n</tr>\n<tr>\n<td>Incidence of injury &amp; failure class for &quot;acute kidney injury&quot; (RIFLE defn)</td>\n<td>14%</td>\n<td>8.4%</td>\n<td>&lt;0.001</td>\n<td>0.52</td>\n</tr>\n<tr>\n<td>Use of renal replacement therapy (RRT)</td>\n<td>10%</td>\n<td>6.3%</td>\n<td>0.005</td>\n<td>0.52</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Bottom line:</strong> Chloride-rich IV fluids were associated w/ greater acute kidney injury and need for RRT in ICU patients, compared to chloride-restrictive IV fluids. </p>\n<p><strong>NOTE:</strong> There was, however, NO difference in mortality, hospital, ICU length of stay, or RRT after hospital discharge.</p>\n<h2 id=\"references\">References</h2>\n<ul>\n<li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=23073953\">Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA. 2012 Oct 17;308(15):1566-72. doi: 10.1001/jama.2012.13356.</a></li>\n<li><a href=\"http://www.medscape.org/viewarticle/503138%20\">http://www.medscape.org/viewarticle/503138</a></li>\n</ul>\n"}}